A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

NCT02616185 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
91
Enrollment
INDUSTRY
Sponsor class

Stopped Due to strategic evaluation of PF-06753512 (VBIR-1) within context of Pfizer's oncology portfolio, decision not based on any safety or regulatory concerns.

Conditions

Interventions

Sponsor

Pfizer